Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002339 · ClinicalTrials.gov registry record · Phase 3
A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00002339: Completed Phase 3 study, sponsored by Pfizer.
NCT00002339 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002339, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.
Interventions
- DRUG Fluconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Phase | Phase 3 |
What the finished NCT00002339 record still lists
NCT00002339 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluconazole is the first listed.
NCT00002339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002339 about?
NCT00002339 is a clinical study titled "A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems". To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.
What is the current status of trial NCT00002339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants.
What interventions are being tested in trial NCT00002339?
The interventions under investigation include: Fluconazole (DRUG).
Who is sponsoring clinical trial NCT00002339?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002339's enrollment target sits among peer trials
100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning